Bóng Scoring for Peripheral Blood Vessel Trifecta - Vietnam Registration 240001967/PCBB-HCM
Access comprehensive regulatory information for Bóng Scoring for Peripheral Blood Vessel Trifecta in Vietnam's medical device market through Pure Global AI's free database. This Risk Class TBYT Loại B medical device is registered under number 240001967/PCBB-HCM and manufactured by BrosMed Medical Co.,Ltd.. The authorized representative in Vietnam is CÔNG TY TNHH TRANG THIẾT BỊ Y TẾ TRUNG HIẾU.
This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 300,000+ Vietnamese medical device registrations, helping global MedTech companies navigate Vietnam MOH regulations, identify competitors, and discover partnership opportunities efficiently.
Device Details
Registration Details
240001967/PCBB-HCM
000.00.19.H29-240827-0010
Tri-Wedge PTA Scoring Balloon Dilatation Catheter
21-18S32; 21-18S33; 21-18S34; 21-18S36; 21-18S42; 21-18S43; 21-18S44; 21-18S46; 21-18S52; 21-18S53; 21-18S54; 21-18S56; 21-18S62; 21-18S63; 21-18S64; 21-18S66; 21-18S72; 21-18S73; 21-18S74; 21-18S76; 21-18S82; 21-18S83; 21-18S84; 21-18S86; 21-18L32; 21-18L33; 21-18L34; 21-18L36; 21-18L42; 21-18L43; 21-18L44; 21-18L46; 21-18L52; 21-18L53; 21-18L54; 21-18L56; 21-18L62; 21-18L63; 21-18L64; 21-18L66; 21-18L72; 21-18L73; 21-18L74; 21-18L76; 21-18L82; 21-18L83; 21-18L84; 21-18L86; 21-35S32; 21-35S33; 21-35S34; 21-35S36; 21-35S42; 21-35S43; 21-35S44; 21-35S46; 21-35S52; 21-35S53; 21-35S54; 21-35S56; 21-35S62; 21-35S63; 21-35S64; 21-35S66; 21-35S72; 21-35S73; 21-35S74; 21-35S76; 21-35S82; 21-35S83; 21-35S84; 21-35S86; 21-35L32; 21-35L33; 21-35L34; 21-35L36; 21-35L42; 21-35L43; 21-35L44; 21-35L46; 21-35L52; 21-35L53; 21-35L54; 21-35L56; 21-35L62; 21-35L63; 21-35L64; 21-35L66; 21-35L72; 21-35L73; 21-35L74; 21-35L76; 21-35L82; 21-35L83; 21-35L84; 21-35L86
Technical Details
Peripheral blood vessel dilation is indicated to dilate the narrow areas of the femoral, popliteal, tibial, and tibioperoneal arteries and the renal arteries, and to treat the obstructive damage of the natural or synthetic arteriovenous fistulae' filtration holes
Dates and Status
Aug 29, 2024